April 21, 2026
2 min watch
In this video, Ursula A. Matulonis, MD, shares insight on the phase 3 KEYNOTE-B96 trial of pembrolizumab combination therapy vs. placebo in patients with PD-L1-positive, platinum-resistant ovarian cancer.
In the trial, presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, patients received pembrolizumab (Keytruda, Merck) plus weekly paclitaxel, with or without bevacizumab (Avastin, Genentech), or placebo.
Matulonis, chief of the division of gynecologic oncology at Dana-Farber Cancer Institute, reported improvements in PFS and OS with the pembrolizumab regimen were “statistically significant.”
“[This] certainly represents another option for patients,” Matulonis told Healio. “It’s now fully FDA approved … and in this entry criteria, patients could have received up to two prior lines [of treatment]. It’ll be important to think about these as considerations when talking to patients with platinum-resistant ovarian cancer about their options.”
For more information:
Ursula A. Matulonis, MD, can be reached at ursula_matulonis@dfci.harvard.edu.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Zsiros E, et al. Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab vs. placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer. Presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; April 10-13, 2026; San Juan, Puerto Rico.
Disclosures:
Healio could not determine relevant financial disclosures at the time of publication.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply